Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection

Table 3 Cox regression analysis of factors associated with overall survival of hepatitis C virus after inverse probability of treatment weighting in patients who achieved sustained virologic response

Variables	Crude HR (95%CI)	P value	Adjusted HR (95%CI)	P value
Group		0.360		0.280
HCV mono-infection	1 (reference)		1 (reference)
HIV/HCV co-infection	0.37 (0.05-3.07)		0.46 (0.11-1.91)
Age (year)		0.002		0.009
< 65	1 (reference)		1 (reference)
≥ 65	3.35 (1.54-7.30)		2.45 (1.21-4.96)
Sex		0.288
Male	1 (reference)
Female	0.68 (0.33-1.39)
Diabetes mellitus		0.002		0.042
Absent	1 (reference)		1 (reference)
Present	3.11 (1.54-6.27)		2.04 (1.03-4.05)
Hypertension		0.104
Absent	1 (reference)
Present	0.35 (0.10-1.24)
Child-Pugh score		0.804
A	1 (reference)
B	1.02 (0.90-1.14)
Treatment		0.035		0.184
Peginterferon plus ribavirin	1 (reference)		1 (reference)
DAA	2.76 (1.07-7.09)		1.95 (0.74-5.15)
Fibrosis-4 index		< 0.001		0.649
≤ 3.25	1 (reference)		1 (reference)
> 3.25	1.26 (1.24-1.97)		1.13 (0.67-1.93)
Liver cirrhosis		< 0.001		0.005
Absent	1 (reference)		1 (reference)
Present	5.18 (2.81-9.55)		2.72 (1.34-5.52)
AFP (ng/mL)		0.580
< 20	1 (reference)
≥ 20	1.04 (0.91-1.17)
ALBI score		< 0.001		0.039
≤ -2.60	1 (reference)		1 (reference)
> -2.60	3.55 (1.82-6.91)		1.97 (1.04-3.73)
APRI		0.026		0.791
< 1	1 (reference)		1 (reference)
≥ 1	2.21 (1.10-4.44)		1.10 (0.54-2.25)

HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; DAA: Direct-acting antiviral; AFP: Alpha-fetoprotein; ALBI: Albumin-bilirubin score; APRI: Aspartate aminotransferase to platelet ratio index; HR: Hazard ratio; 95%CI: 95% confidence interval.